Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors

BACKGROUND: Anti-PD-(L)1 agents are standard of care treatments in various cancers but predictive factors for therapy selection are limited. We hypothesised that markers of systemic inflammation would predict adverse outcomes in multiple cancers treated with anti-PD-(L)1 agents. MATERIAL AND METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Iivanainen, Sanna, Ahvonen, Jarkko, Knuuttila, Aija, Tiainen, Satu, Koivunen, Jussi Pekka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735669/
https://www.ncbi.nlm.nih.gov/pubmed/31555483
http://dx.doi.org/10.1136/esmoopen-2019-000531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735669/
https://www.ncbi.nlm.nih.gov/pubmed/31555483
http://dx.doi.org/10.1136/esmoopen-2019-000531

Ejemplares similares